Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma

Dipti Rao, Anouk Van Berkel, Ianthe Piscaer, William F. Young, Lucinda Gruber, Timo Deutschbein, Martin Fassnacht, Felix Beuschlein, Ariadni Spyroglou, Aleksander Prejbisz, Katarzyna Hanus, Graeme Eisenhofer, Massimo Manelli, Letizia Canu, Jacques W.M. Lenders, Irina Bancos, Henri J.L.M. Timmers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Context: Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design: International multicenter retrospective study. Intervention: None. Patients: Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures: Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results: The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions: For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.

Original languageEnglish (US)
Article numberjcem_201802355
Pages (from-to)3812-3820
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume104
Issue number9
DOIs
StatePublished - Apr 11 2019

Fingerprint

Paraganglioma
Pheochromocytoma
Radionuclide Imaging
Magnetic resonance imaging
Decision making
Imaging techniques
Clinical Decision-Making
Diagnostic Imaging
Multicenter Studies
Retrospective Studies
Tumors
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Rao, D., Van Berkel, A., Piscaer, I., Young, W. F., Gruber, L., Deutschbein, T., ... Timmers, H. J. L. M. (2019). Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 104(9), 3812-3820. [jcem_201802355]. https://doi.org/10.1210/jc.2018-02355

Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. / Rao, Dipti; Van Berkel, Anouk; Piscaer, Ianthe; Young, William F.; Gruber, Lucinda; Deutschbein, Timo; Fassnacht, Martin; Beuschlein, Felix; Spyroglou, Ariadni; Prejbisz, Aleksander; Hanus, Katarzyna; Eisenhofer, Graeme; Manelli, Massimo; Canu, Letizia; Lenders, Jacques W.M.; Bancos, Irina; Timmers, Henri J.L.M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 104, No. 9, jcem_201802355, 11.04.2019, p. 3812-3820.

Research output: Contribution to journalArticle

Rao, D, Van Berkel, A, Piscaer, I, Young, WF, Gruber, L, Deutschbein, T, Fassnacht, M, Beuschlein, F, Spyroglou, A, Prejbisz, A, Hanus, K, Eisenhofer, G, Manelli, M, Canu, L, Lenders, JWM, Bancos, I & Timmers, HJLM 2019, 'Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma', Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 9, jcem_201802355, pp. 3812-3820. https://doi.org/10.1210/jc.2018-02355
Rao, Dipti ; Van Berkel, Anouk ; Piscaer, Ianthe ; Young, William F. ; Gruber, Lucinda ; Deutschbein, Timo ; Fassnacht, Martin ; Beuschlein, Felix ; Spyroglou, Ariadni ; Prejbisz, Aleksander ; Hanus, Katarzyna ; Eisenhofer, Graeme ; Manelli, Massimo ; Canu, Letizia ; Lenders, Jacques W.M. ; Bancos, Irina ; Timmers, Henri J.L.M. / Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. In: Journal of Clinical Endocrinology and Metabolism. 2019 ; Vol. 104, No. 9. pp. 3812-3820.
@article{a97ecc1ec55541b9a49b4cdb222a4dd7,
title = "Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma",
abstract = "Context: Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design: International multicenter retrospective study. Intervention: None. Patients: Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures: Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results: The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8{\%}, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2{\%}: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1{\%}: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions: For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.",
author = "Dipti Rao and {Van Berkel}, Anouk and Ianthe Piscaer and Young, {William F.} and Lucinda Gruber and Timo Deutschbein and Martin Fassnacht and Felix Beuschlein and Ariadni Spyroglou and Aleksander Prejbisz and Katarzyna Hanus and Graeme Eisenhofer and Massimo Manelli and Letizia Canu and Lenders, {Jacques W.M.} and Irina Bancos and Timmers, {Henri J.L.M.}",
year = "2019",
month = "4",
day = "11",
doi = "10.1210/jc.2018-02355",
language = "English (US)",
volume = "104",
pages = "3812--3820",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma

AU - Rao, Dipti

AU - Van Berkel, Anouk

AU - Piscaer, Ianthe

AU - Young, William F.

AU - Gruber, Lucinda

AU - Deutschbein, Timo

AU - Fassnacht, Martin

AU - Beuschlein, Felix

AU - Spyroglou, Ariadni

AU - Prejbisz, Aleksander

AU - Hanus, Katarzyna

AU - Eisenhofer, Graeme

AU - Manelli, Massimo

AU - Canu, Letizia

AU - Lenders, Jacques W.M.

AU - Bancos, Irina

AU - Timmers, Henri J.L.M.

PY - 2019/4/11

Y1 - 2019/4/11

N2 - Context: Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design: International multicenter retrospective study. Intervention: None. Patients: Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures: Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results: The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions: For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.

AB - Context: Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design: International multicenter retrospective study. Intervention: None. Patients: Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures: Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results: The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions: For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.

UR - http://www.scopus.com/inward/record.url?scp=85073899852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073899852&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-02355

DO - 10.1210/jc.2018-02355

M3 - Article

AN - SCOPUS:85073899852

VL - 104

SP - 3812

EP - 3820

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

M1 - jcem_201802355

ER -